Nucleoside analogues have been in clinical use for many years, but there are ongoing efforts to improve patient response rates and reduce side effects. Here, the authors highlight recent progress in the development of new nucleoside and nucleotide analogues for the treatment of cancer and viral diseases.
- Lars Petter Jordheim
- David Durantel
- Charles Dumontet